Completed PHASE2 INTERVENTIONAL NCT00212693

Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

Sponsor: Ono Pharmaceutical Co. Ltd

Interventions ONO-2506PO

Updated 5 times since 2017 Last updated: Oct 10, 2012 Started: Jan 31, 2004 Primary completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00212693, this PHASE2 trial focuses on Parkinson's Disease and remains completed. Sponsored by Ono Pharmaceutical Co. Ltd, it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ono Pharmaceutical Co. Ltd

Data source: Ono Pharmaceutical Co. Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.